GENE ONLINE|News &
Opinion
Blog

2022-03-10|

BioNTech and Regeneron Expands Cancer Vaccine Collab, Adds Lung Cancer Indication

by Joy Lin
Share To

BioNTech and Regeneron have been combining the former’s mRNA-based FixVac platform with the latter’s PD-1 immune checkpoint inhibitor, Libtayo, to generate cancer vaccines. Now, the two companies are adding a third tumor type – advanced non-small cell lung cancer (NSCLC) – to their collaboration. 

NSCLC is one of the most common forms of lung cancer, making up about 85% of all lung cancers.

Under the deal, the companies will start evaluating BioNTech’s candidate BNT116 with Libtayo as a first-line treatment for patients with advanced NSCLC. The companies will equally share development costs for the trials. Separately, BioNTech wll conduct a Phase 1 called LuCa-MERIT-1 assessing the BNT116/Libtayo combo in other NSCLC subpopulations. Full financial details of the deal have not been disclosed, similar to previous agreements. 

“We are delighted to expand our collaboration with BioNTech to a third tumor type – advanced NSCLC – and investigate whether combining Libtayo with BNT116 will further enhance the efficacy and safety we’ve demonstrated with Libtayo in this cancer as both a monotherapy and in combination with chemotherapy,” said Israel Lowy, Senior Vice President of Clinical Development, Oncology, at Regeneron. “Combining PD-1 inhibition with mRNA-based vaccines is an exciting, yet still emerging, approach in oncology.”

 

Related article: New Research on Neoantigens and Tumor-targeting T-cells Marks Paradigm Shift in Countering Solid Tumors

 

FixVac and Cancer Vaccine Candidates

 

BioNTech’s FixVac selects combinations of mRNA encoding for known cancer-specific antigens expressed by many cancerous cells. In the case of BNT116, the mRNA vaccine candidate encodes for a cluster of antigens frequently seen on NSCLC cells. 

Besides NSCLC, BioNTech has ongoing partnerships with Regeneron to develop cancer vaccines against advanced melanoma and prostate cancer. The experimental shots also use a combination of FixVac candidates and Libtayo.

Outside the partnership, BioNTech’s FixVac pipeline includes a Phase 2 asset for HPV-positive head and neck cancers and a Phase 1 drug for ovarian cancer. 

“Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform,” said Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech.

The five-year survival rate of advanced NSCLC is only 25% leaving patients, and there are few treatment options. 

“We believe that a potent vaccine that induces strong T cell responses against shared tumor associated antigens combined with PD-1 blockade that further enables the activated T cell repertoire will help to address the high unmet medical need in this indication,” said Türeci.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Mayo Clinic Researchers Invent Hypothesis-Driven AI for Cancer Research Breakthroughs
2024-03-14
Parexel and Japanese Foundation for Cancer Research Collaborate to Boost Oncology Clinical Trials in Japan
2024-01-18
JPM 2024: Generative AI Reshapes Medical Paradigms, Transforming the Past
2024-01-15
LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top